Assessment of Residual‐Serum SARS‐CoV‐2‐N‐Antigen Testing for Hospital Surveillance in Germany
Journal of Medical Virology · 2026
DOI: 10.1002/jmv.71055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2026. Verfasst von Jasmin Weninger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Knappschaft Kliniken University Hospital Bochum, Ruhr University Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Antigens, Viral, COVID-19 Serological Testing. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Routine SARS‐CoV‐2 surveillance in hospitals is crucial for preventing in‐hospital transmission, especially among elderly and multimorbid patients. While RT‐PCR testing is sensitive, it is resource‐intensive, and rapid antigen tests lack sensitivity. This study evaluates the diagnostic performance and utility of serum N‐antigen ELISA for detecting active SARS‐CoV‐2 infection in hospitalized patients during the Omicron period. A prospective, non‐interventional diagnostic accuracy study was conducted at a tertiary‐care university hospital in Germany from 6 January to 8 February 2023. Residual serum samples were tested for N‐antigen using a commercial ELISA and compared with RT‐PCR results from respiratory swabs. Diagnostic latency, sensitivity, specificity, and predictive values were calculated at the sample and patient levels. Among 2030 inpatients (12,558 patient‐days), 610 were screened by ELISA. Sensitivity and specificity were 60.6% and 99.9%, respectively, increasing to 89.6% and 99.9% for samples with ≥ 10 4 genome equivalents/mL. Early infection showed higher sensitivity (78.6%) compared to late infection (25.5%). In a paired same‐cohort PCR‐only scenario, the combined PCR plus available serum N‐antigen workflow reduced unknown‐risk time by 243 patient‐days, corresponding to 1.94 fewer unknown‐risk days per 100 cohort patient‐days (95% bootstrap CI, 1.38–2.57). Residual‐serum SARS‐CoV‐2 N‐antigen testing offers high specificity and early‐phase sensitivity, complementing PCR‐based hospital surveillance without additional sampling. This approach may enhance the efficient detection of unsuspected infections in routine inpatient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Knappschaft Kliniken University Hospital Bochum, Ruhr University Bochum, Bochum, Germany.
- Department of Medical Biochemistry, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
- Bundeswehr Institute of Microbiology, Munich, Germany.
ORCID-Profile: Jasmin Weninger, Michael Pohl, Abdurrahman Coskun
Zitieren
APA
Weninger, J., Zedginidze, A., Katsounas, A., Pohl, M., Coskun, A., Wölfel, R., & Özcürümez, M. (2026). Assessment of Residual‐Serum SARS‐CoV‐2‐N‐Antigen Testing for Hospital Surveillance in Germany. Journal of Medical Virology. https://doi.org/10.1002/jmv.71055
Vancouver
Weninger J, Zedginidze A, Katsounas A, Pohl M, Coskun A, Wölfel R, et al. Assessment of Residual‐Serum SARS‐CoV‐2‐N‐Antigen Testing for Hospital Surveillance in Germany. Journal of Medical Virology. 2026. doi:10.1002/jmv.71055
BibTeX
@article{Weninger2026,
author = {Weninger, Jasmin and Zedginidze, Aleko and Katsounas, Antonios and Pohl, Michael and Coskun, Abdurrahman and Wölfel, Roman and Özcürümez, Mustafa},
title = {Assessment of Residual‐Serum SARS‐CoV‐2‐N‐Antigen Testing for Hospital Surveillance in Germany},
journal = {Journal of Medical Virology},
year = {2026},
doi = {10.1002/jmv.71055}
}
EUVIMED